SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 14, 2018
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
2600 Glostrup (Copenhagen)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Furnished as Exhibit 3.1 to this Report on Form 6-K are the Articles of Association of Zealand Pharma A/S, or the Company.
On September 14, 2018, the Company has increased its share capital by a nominal amount of DKK 7,500 divided into 7,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of the Companys employee warrant programs.
The exercise price was DKK 101.20 per share and the total proceeds to Zealand from the capital increase amount to DKK 759,000.00.
The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 30,758,827 divided into 30,758,827 shares with a nominal value of DKK 1 each.
The amendment to the Companys Articles of Association resulting from the share capital increase has today been registered with the Danish Business Authority and is included as Exhibit 3.1 hereto and incorporated by reference herein
Reference is made to the Exhibit Index included hereto.